Elementis plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELMTY research report →
Price Chart
About the company
Elementis plc operates as a specialty chemical company in the United Kingdom, rest of Europe, North America, and internationally. It operates in two segments, Coatings and Personal Care. The Coatings segment offers production of rheological modifiers and additives for decorative and industrial coatings; and performance chemicals for the energy sector.
- CEO
- Lucas van Ravenstein
- IPO
- 2013
- Employees
- 989
- HQ
- London, GL, GB
Get TickerSpark's AI analysis on ELMTY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.32B
- P/E
- 19.12
- Fwd P/E
- 15.39
- PEG
- 0.08
- P/S
- 2.30
- P/B
- 2.13
- EV/EBITDA
- 9.70
- Div Yield
- 1.76%
- Gross Margin
- 48.57%
- Op Margin
- 19.92%
- Net Margin
- 12.16%
- ROE
- 11.29%
- ROIC
- 8.29%
Latest fiscal year · YoY change
- Revenue
- $598.90M-18.9%
- Gross Profit
- $279.15M-17.4%
- Op Income
- $105.04M
- Net Income
- $-45,606,327+4.6%
- EPS
- $-0.31+4.7%
- OCF Growth
- -24.6%
- FCF Growth
- -14.8%
- 52W High
- $11.40
- 52W Low
- $7.31
- 50D MA
- $9.37
- 200D MA
- $8.44
- Beta
- 0.97
- RSI (14)
- 50
- Avg Volume
- 6
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Elementis delivered higher adjusted profit and margins in 2025 despite softer demand, while continuing to simplify the portfolio and guide to further organic growth and margin expansion in 2026.· March 5, 2026
- Adjusted operating profit rose 4.6% to $126.7 million and adjusted EPS increased 14.2% to $0.137.
- Revenue was down 1% reported to $597.5 million, but price actions and cost savings helped offset weak volumes.
- Personal Care outperformed with revenue up 2.4% to $224.5 million and margin expanding to 32.4%.
- Coatings remained resilient in a weak market, with revenue of $373 million and margin of 18.9%.
- Elementis announced the sale of its pharmaceutical manufacturing business and expects to return the net proceeds to shareholders after closing.
For 2025, Elementis reported revenue of $597.5 million, down 1% reported and 1.9% on a constant-currency basis. Adjusted operating profit increased 4.6% to $126.7 million, adjusted operating margin improved 150 basis points to 21.2%, and adjusted EPS rose 14.2% to $0.137. Free cash flow was $41 million versus $51 million a year ago, and net debt ended at $185.4 million with leverage of 1.3x. In Personal Care, revenue rose 2.4% to $224.5 million and adjusted operating profit was $72.8 million, with margin up to 32.4%. In Coatings, revenue was $373 million versus $386.4 million last year and adjusted operating profit was $70.4 million, with margin at 18.9%. For 2026, management said it expects a solid start to continue, a typical 52-48 seasonal split, incremental $4 million of savings, CapEx of 4% to 5% of revenue, a small working-capital outflow, and leverage around 1x by the end of 2026 on an organic basis. The company also said the pharma sale should close in Q2 and that net proceeds are expected to be distributed to shareholders.
Luc Van Ravenstein emphasized that 2025 validated the company’s reshaped portfolio: Elementis is now focused on Personal Care and Coatings after exiting Talc and Chromium, and it will soon exit pharma manufacturing as well. His tone was upbeat and confident, highlighting record innovation sales of 16.4%, zero lost-time accidents, and progress on strategic priorities such as customer service, simplification, and innovation-led growth. He repeatedly framed future margin improvement as coming mainly from organic growth in higher-margin areas rather than from large-scale restructuring.
Katharina Helen Kearney-Croft said the business held up well in a difficult market, with revenue down only slightly while adjusted operating profit, EPS, and margins improved. She cited $18 million of total cost savings in 2025, free cash flow of $41 million, adjusted operating cash flow of $104.7 million, and a year-end net debt balance of $185.4 million after the Alchemy acquisition, the Talc proceeds, buybacks, dividends, and other cash movements. She also said the board recommended a final dividend of $0.03, taking the full-year dividend to $0.043, up 7.5%, and that 2026 CapEx should be 4% to 5% of revenue with a small working-capital outflow and leverage expected to move toward about 1x.
Analysts pressed management on whether growth would come from bolt-on M&A or organic expansion, and Luc said the strategy is clearly organic-led, with acquisitions used selectively only when accretive, as Alchemy was. Questions also focused on margin progression toward the 23%+ target and how the divisions differ; management said the gap should be bridged mainly through higher-margin growth, mix improvement, remaining savings, and Personal Care’s stronger structural margins. On capital returns, management said the pharma sale proceeds are expected to be distributed to shareholders after closing, but they would wait until completion before adjusting numbers. Analysts also asked about Q1 and 2026 volume growth; management said the year started solidly, they are comfortable with consensus, and they expect a typical seasonal split, while noting geopolitics remain an external uncertainty.
The company showed it can grow profit and margins even in a soft demand backdrop, with price, cost savings, and mix offsetting weaker volumes. Management sees further upside from innovation, higher R&D, customer intimacy, and margin-accretive growth areas such as hectorite, skincare, and selected adjacent markets.
Revenue was still down and Coatings volumes were pressured by weak industrial and decorative end markets, while free cash flow fell versus last year due to working capital outflow and higher capex. Management also flagged geopolitical uncertainty, a small expected 2026 working-capital outflow, and the fact that some margin improvement from cost actions is becoming harder to repeat at the same pace.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 100.0%
- Shares Outstanding
- 140.92M
- Float Shares
- 140.91M
Our ELMTY coverage
Recent articles, reports, and earnings notes.
No research on ELMTY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ELMTY report →Are Basic Materials Stocks Lagging ELEMENTIS (ELMTY) This Year?
zacks.com · Nov 20
Elementis (OTCMKTS:ELMTY) Shares Shorted: Short Interest Down 76.2% in September
defenseworld.net · Oct 12
Elementis (OTCMKTS:ELMTY) Hits New 1-Year High – Here’s What Happened
defenseworld.net · Sep 4
Elementis plc (ELMTY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 30
Elementis H1 Earnings Call Highlights
marketbeat.com · Jul 30
Elementis jumps after selling pharma manufacturing arm to AB Foods
proactiveinvestors.co.uk · Jun 2
Artisan International Explorer Fund Q1 2026 Winners, Laggards, Buys And Sells
seekingalpha.com · May 13
Orion (NYSE:OEC) and Elementis (OTCMKTS:ELMTY) Critical Analysis
defenseworld.net · Apr 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.